Skip to content

Study · Non-randomized trial · 2022

3 results

Effect of Intranasal Oxytocin on Resting-state Effective Connectivity in Schizophrenia.

Korann V, Jacob A, Lu B, Devi P, Thonse U, Nagendra B, Maria Chacko D, Dey A, Padmanabha A, Shivakumar V, Dawn Bharath R, Kumar V and 4 more

Show all authors

Varambally S, Venkatasubramanian G, Deshpande G, Rao NP

Schizophrenia bulletin1 Sept 2022Cited by 19 (Europe PMC)

PMID35759349 (opens in a new tab)PMCIDPMC9434443 (opens in a new tab)DOI10.1093/schbul/sbac066 (opens in a new tab)PepBankPUB-35759349
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialMechanism

    In male patients with schizophrenia and healthy volunteers, oxytocin but not placebo increased the strength of effective connectivity from the left caudate to three regions.

    In plain wordsIn men with schizophrenia and healthy men, oxytocin, but not placebo, strengthened brain connections from the left caudate.

    Peptide
    Oxytocin
    Outcome
    IncreaseEffective connectivity from left caudate to motor and frontal regions
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Oxytocin, but not placebo, significantly increased the strength of connectivity in these connections.
    1 context sentence
    Summary · context
    31 male patients with schizophrenia (SCZ) and 21 healthy male volunteers (HV) underwent resting functional magnetic resonance imaging scans with intra-nasal oxytocin (24 IU) and placebo administered in counterbalanced order.
  2. 02HumanNon-randomized trialMechanism

    In male patients with schizophrenia, better cognitive insight was associated with a greater increase in connectivity with oxytocin.

    In plain wordsIn men with schizophrenia, better insight was linked to a bigger rise in brain connectivity with oxytocin.

    Peptide
    Oxytocin
    Outcome
    Not applicableConnectivity increase with oxytocin and cognitive insight
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Better cognitive insight and lower negative symptoms were associated with a greater increase in connectivity with oxytocin.
    1 context sentence
    Summary · context
    31 male patients with schizophrenia (SCZ) and 21 healthy male volunteers (HV) underwent resting functional magnetic resonance imaging scans with intra-nasal oxytocin (24 IU) and placebo administered in counterbalanced order.
  3. 03HumanNon-randomized trialMechanism

    In male patients with schizophrenia, lower negative symptoms were associated with a greater increase in connectivity with oxytocin.

    In plain wordsIn men with schizophrenia, fewer negative symptoms were linked to a bigger rise in brain connectivity with oxytocin.

    Peptide
    Oxytocin
    Outcome
    Not applicableConnectivity increase with oxytocin and negative symptoms
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Better cognitive insight and lower negative symptoms were associated with a greater increase in connectivity with oxytocin.
    1 context sentence
    Summary · context
    31 male patients with schizophrenia (SCZ) and 21 healthy male volunteers (HV) underwent resting functional magnetic resonance imaging scans with intra-nasal oxytocin (24 IU) and placebo administered in counterbalanced order.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.